BeiGene (HKSE:06160) Ending Cash Position : HK$21,140 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Ending Cash Position?

BeiGene's Ending Cash Position for the quarter that ended in Sep. 2024 was HK$21,140 Mil.

BeiGene's quarterly Ending Cash Position declined from Mar. 2024 (HK$21,963 Mil) to Jun. 2024 (HK$20,446 Mil) but then increased from Jun. 2024 (HK$20,446 Mil) to Sep. 2024 (HK$21,140 Mil).

BeiGene's annual Ending Cash Position declined from Dec. 2021 (HK$34,182 Mil) to Dec. 2022 (HK$30,169 Mil) and declined from Dec. 2022 (HK$30,169 Mil) to Dec. 2023 (HK$24,882 Mil).

BeiGene Ending Cash Position Historical Data

The historical data trend for BeiGene's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Ending Cash Position Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

4,844.84

10,775.18

34,182.14

30,168.71

24,881.90

BeiGene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Ending Cash Position	Get a 7-Day Free Trial															24,118.76	24,881.90	21,962.57	20,446.04	21,140.32

BeiGene Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BeiGene's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	30263.264	+	-5381.366
	=	24,882

BeiGene's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	20396.301	+	744.017
	=	21,140

BeiGene Ending Cash Position Related Terms

Thank you for viewing the detailed overview of BeiGene's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

BEIGF:USA BGNE:USA 49B:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

Executives

Oyler John Victor	2101 Beneficial owner
Jpmorgan Chase & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene Headlines

No Headlines